{"id":"placebo-for-isradipine","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1648","moleculeType":"Small molecule","molecularWeight":"371.39"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo serves as a negative control in randomized controlled trials to establish the efficacy of the active drug (isradipine) by comparison. Any therapeutic effects observed in the placebo group are attributed to natural disease progression, regression to the mean, or the placebo effect itself. This allows researchers to isolate the true pharmacological benefit of isradipine.","oneSentence":"Placebo has no active pharmacological mechanism; it is an inert control substance used in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:13.008Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in Phase 3 trial for Parkinson's disease (isradipine comparison)"}]},"trialDetails":[{"nctId":"NCT03083353","phase":"EARLY_PHASE1","title":"Isradipine Enhancement of Virtual Reality Cue Exposure for Smoking Cessation","status":"COMPLETED","sponsor":"University of Texas at Austin","startDate":"2020-01-22","conditions":"Nicotine Dependence, Smoking, Cigarette, Smoking Cessation","enrollment":78},{"nctId":"NCT03538262","phase":"","title":"Assessing Tele-Health Outcomes in Multiyear Extensions of PD Trials","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2018-10-01","conditions":"Parkinson Disease","enrollment":226},{"nctId":"NCT02168842","phase":"PHASE3","title":"Efficacy of Isradipine in Early Parkinson Disease","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2014-11","conditions":"Parkinson Disease","enrollment":336},{"nctId":"NCT01895270","phase":"PHASE1, PHASE2","title":"Improving Buprenorphine Detoxification Outcomes With Isradipine","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2013-10","conditions":"Opioid Dependence","enrollment":28},{"nctId":"NCT01784666","phase":"PHASE2","title":"Adjunctive Isradipine for the Treatment of Bipolar Depression","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2013-02","conditions":"Bipolar Disorder","enrollment":2}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":242,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo (for Isradipine)","genericName":"Placebo (for Isradipine)","companyName":"University of Rochester","companyId":"university-of-rochester","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo has no active pharmacological mechanism; it is an inert control substance used in clinical trials. Used for Control arm in Phase 3 trial for Parkinson's disease (isradipine comparison).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}